Rubraca (rucaparib) — Medica
Pancreatic Adenocarcinoma
Initial criteria
- age ≥ 18 years
- Patient has a BRCA mutation or PALB2 mutation
- Patient has tried platinum-based chemotherapy
- Patient has not had disease progression following the most recent platinum-based chemotherapy
Approval duration
1 year